Laura Zarbo

Dr. Laura Zarbo

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2025 in ChemMedChem
Verified
Journal Article
Open access
Valentina Noemi MadiaValentina Noemi Madia
Valentina Noemi Madia
RERoberta Emmolo
Roberta Emmolo
Elisa PatacchiniElisa Patacchini
Elisa Patacchini
DADonatella Amatore
Donatella Amatore
SMStefania Maloccu
Stefania Maloccu
Roberta CostiRoberta Costi
Roberta Costi
It has been more than four years since the first report of SARS‐CoV‐2, the virus responsible for the coronavirus disease 2019 (COVID‐19) pandemic, the scientific community is focused on vaccine development in an exceptionally rapid time frame, as well as the evaluation of a wide range of potential treatments in clinical trials, a few of which have also reached the market. However, these drugs are characterized by several limits (including low response to treatment in some patients, low effectiveness against the new variants, severe side effects, etc.), thus underscoring the need to speed up the research. Among potential antiviral targets, the SARS‐CoV‐2 nonstructural protein 13 (nsp13) is highly promising thanks to its pivotal role in viral replication. Pursuing the studies on the development of nsp13 inhibitors, herein, the design, synthesis, and biological evaluation of new SARS‐CoV‐2 nsp13 inhibitors are reported. In general, the newly designed dikehexenoic derivatives are proven active against both the enzymatic activities showing measurable IC50 under 30 μM concentration, while the diketobutanoic series shows less promising results. Moreover, the tested compounds are capable of blocking viral replication without exerting cytotoxicity. Docking studies predict their binding into an allosteric pocket within the RecA2 domain.

9 June 2025 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
Valentina Noemi MadiaValentina Noemi Madia
Valentina Noemi Madia
NGNadia Garibaldi
Nadia Garibaldi
DIDavide Ialongo
Davide Ialongo
Elisa PatacchiniElisa Patacchini
Elisa Patacchini
VTValeria Tudino
Valeria Tudino
Roberta CostiRoberta Costi
Roberta Costi
Terminal deoxynucleotidyl transferase (TdT) is overexpressed in some cancer types, where it drives the mutagenic repair of double strand breaks through non canonical non-homologous end joining pathway. The TdT enzyme belongs to the X family of polymerases, together with the DNA polymerase λ (pol λ) and β (pol β). However, TdT exclusively displays template-independent nucleotide polymerisation. Pursuing our studies in developing TdT inhibitors, herein we deepened the structure-activity relationships of new structural analogues of our previously identified hit compounds. The diketo hexenoic acid derivatives here analysed showed high selectivity towards TdT and inhibition potencies spanning from the low micromolar range to the nanomolar. Docking studies highlighted the chemical features involved in the TdT binding, well contributing to the rationalisation of the structural requirements needed for the enzymatic inhibition.

22 August 2026 in ChemMedChem
Verified
Journal Article
Open access
PDF file
Francesco SaccolitiFrancesco Saccoliti
Francesco Saccoliti
Elisa PatacchiniElisa Patacchini
Elisa Patacchini
ECEmanuele Cara
Emanuele Cara
LZLaura Zarbo
Laura Zarbo
AMAntonella Messore
Antonella Messore
RSRoberto Di Santo
Roberto Di Santo
Given its pivotal role in the viral life cycle, blocking integrase (IN) through IN strand transfer inhibitors (INSTIs) represented a breakthrough in the treatment of HIV infection, establishing these antiretroviral regimens as first‐line options against AIDS. However, the onset of drug‐resistant strains has challenged the efficacy of INSTIs, demanding new efforts in the search for therapeutic tools that work through alternative modes of action. In this context, the discovery of allosteric IN inhibitors (ALLINIs) has highlighted new opportunities to target IN beyond its active site, enhancing antiviral efficacy and the genetic barrier to resistance. Extensive drug discovery campaigns have resulted in the development of effective ALLINIs with both in vitro and in vivo efficacy, two of which are advancing in clinical trials as next‐generation therapeutic tools. Nevertheless, advancements in structural biology have critically aided in elucidating the underlying effects of ALLINIs, highlighting a complex, multimodal mode of action that ultimately yields defects in virion maturation. This review focuses on ALLINIs, providing a comprehensive overview of major drug discovery efforts devoted to this field, with an emphasis on the medicinal chemistry and structural biology findings that have revealed unprecedented opportunities for developing innovative and effective anti‐HIV drugs.

7 August 2026 in ACS Infectious Diseases
Verified
Journal Article
Open access
SNSalvatore Nieddu
Salvatore Nieddu
GRGiuseppe Ruggieri
Giuseppe Ruggieri
RSRiccardo De Santis
Riccardo De Santis
PMPaolo Malune
Paolo Malune
Elisa PatacchiniElisa Patacchini
Elisa Patacchini
Francesca EspositoFrancesca Esposito
Francesca Esposito
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still a major public health issue, even today. Among the SARS-CoV-2 nonstructural proteins, the main protease (Mpro) plays a critical role in viral polyprotein processing and is therefore indispensable for viral replication. For this reason, it represents one of the most promising therapeutic targets for the development of antiviral agents against SARS-CoV-2. Currently, only one protease antiviral agent (nirmatrelvir) has received emergency approval for COVID-19 treatment, the disease caused by SARS-CoV-2 infection. However, the emergence of viral mutations may compromise its efficacy, highlighting the urgent need to develop new, safe, and effective protease antiviral agents. In the present work, we designed and synthesized new SARS-CoV-2 Mpro small-molecule inhibitors endowed with a pyrimidine scaffold. A series of derivatives were evaluated in both biochemical and cell-based assays to assess their antiviral efficacy, with some of them being able to inhibit the SARS-CoV-2 Mpro activity and to suppress viral replication. Docking studies were confirmed by site-directed mutagenesis, and the mechanism of action of the most promising compound was elucidated.

14 November 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
GRGiuseppe Ruggieri
Giuseppe Ruggieri
Elisa PatacchiniElisa Patacchini
Elisa Patacchini
Antonella MessoreAntonella Messore
Antonella Messore
LZLaura Zarbo
Laura Zarbo
ECEmanuele Cara
Emanuele Cara
Roberta CostiRoberta Costi
Roberta Costi
Background: The development of resistance to conventional therapies remains one of the major challenges in the treatment of breast and colorectal cancers, highlighting the urgent need for novel anticancer agents with improved efficacy. In the present study, a series of novel aroyl pyrrole derivatives was designed and synthesized, evolving from the previously identified hit compound 1a, in order to investigate the influence of structural modifications on antitumor activity. Methods: The antiproliferative activity of all compounds was evaluated in vitro against two human breast cancer cell lines (MCF7 and MDA-MB231) and two colorectal cancer cell lines (HT-29 and RKO). Result: Among the synthesized derivatives, compound 3 emerged as the most active analog, displaying antiproliferative activity at low micromolar concentrations and significantly improved potency compared with the parent compound 1a in all tested cell lines. Furthermore, 3 did not show any significant cytotoxicity toward non-transformed HaCaT keratinocytes and normal dermal fibroblasts, suggesting a remarkable degree of selectivity for tumor cells. Flow cytometric analysis demonstrated that both 1a and 3 induced cell-cycle arrest at the G0/G1 phase in all four cancer cell lines, indicating inhibition of cell-cycle progression as one of the mechanisms underlying their antiproliferative activity. Furthermore, both compounds induce cell death in a small percentage of cells through a caspase-3/7-independent mechanism. Conclusions: Overall, these findings identify 3 as a promising compound for the development of novel pyrrole-based anticancer agents and provide useful information on structure-activity relationships for the future optimization of this chemical scaffold.